AbbVie defeats IPR petition filed by Coherus challenging Humira®
Clients AbbVie Inc.
Jones Day successfully defended AbbVie Inc. in connection with an IPR petition brought by Coherus Biosciences, Inc. against U.S. Patent No. 9,114,166, which is directed to formulations for AbbVie's antibody therapeutic Humira®. Coherus sought to develop and commercialize a biosimilar version of Humira®. Following the filing of the Patent Owner's Preliminary Response by AbbVie, the PTAB denied institution of Coherus's IPR petition with regard to all of the challenged claims.
Coherus Biosciences Inc. v. AbbVie Biotechnology Ltd. et al., IPR2016-01018 (PTAB)